SEC Form 4 · accession 0001104659-16-163871
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger Louis
Officer — See Remarks
Period of report
Dec 22, 2016
Accepted (ET)
Dec 27, 2016 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $8.65 | Dec 22, 2016 | A | 41,740 | A | — | Dec 22, 2026 | Common Shares | 41,740 | 41,740 | D |
Explanation of responses
- F1Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
- F2Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 13,913 common shares underlying this stock option award will vest on December 22, 2017, 13,913 common shares underlying this stock option award will vest on December 22, 2018 and 13,914 common shares underlying this stock option award will vest on December 22, 2019.
Remarks
Global Chief Compliance Officer